25 May 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment and other matters with Medicines Australia acting on behalf of the innovator medicines industry.
The Agreement includes a commitment to seek the advice of the PBAC as to whether the base case discount rate at 3A.1 of the PBAC Guidelines aligns with international best practice.